Category Archives: AP26113 – brigatinib from Ariad

Brigatinib update

Thanks to Dave for pointing this out. This info can be found on Ariad’s site under Investors, presentations. It’s from the Cowan Healthcare presentation which may only be available for a few weeks. The relevant info is on pages 15-16. … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Research | Leave a comment

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Editorial on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients that discusses ALK inhibitors and different kinds of radiation treatments. Treatments discussed include: 1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Survey of ALK inhibitors effects on brain mets

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Ariad’s Brigatinib trial

Ariad has fully enrolled the Phase 2 trial for Brigatinib. It is likly that it is much harder to get into the trial now. I have not heard of them giving ethical exemptions yet. http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2087810

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Ariad plans to file NDA in 3rd quarter of 2016

Ariad plans to file a new drug application (NDA) for brigatnib in 3rd quarter of 2016. http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2075920

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Comparison of 3 ALK inhibitors’ phase 2 trials

All of these results are based on 5 phase 2 trials. However the conditions of each trial may differ in important ways. For example, it is my understanding that the trial for brigatinib was limited to healthier patients while the … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Brigatinib Phase 1/2 trial abstract

Abstract 8062 is about a Phase 1/2 trial. There were 137 treated patients (evaluated for safety) and 72 ALK+ patients (evaluated for efficacy). The patients recieved three different dose levels/combinations.  Please see glossary for acronym definitions. As of 8-4-2014, 71% … Continue reading

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

ASCO links

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro | Leave a comment

Ariad update On Brigatinib

Ariad presented an update on a phase I-II clinical trial. The results are pretty good but confusing. There are three cohorts of Crizotinib resistant patients. A) 90mg daily ongoing, B) 90mg daily for 7 days then 180mg daily ongoing, and … Continue reading

Posted in AP26113 - brigatinib from Ariad, Research | Leave a comment